Green Journals

International Approved Journals

Journal Information

Journal Title	MOLECULAR CANCER THERAPEUTICS
Publisher	AMER ASSOC CANCER RESEARCH
ISSN	1535-7163
E-ISSN	1538-8514
Database	Clarivate
Domain	Health Sciences, Life Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody-Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2026-10-28 Pages OF1-OF13
Authors: Asma Jabeen, Ben Leatherdale, Rebecca Martin et al.
DOI: 10.1158/1535-7163.mct-25-1241

Preclinical modeling of trastuzumab deruxtecan in a mouse model of brain metastatic triple-negative breast cancer identifies two contributors to efficacy.
2026-10-24
Authors: Imran Khan, Dinesh Kumar, Simone Difilippantonio et al.
DOI: 10.1158/1535-7163.mct-26-0592

Inhibition of PLK1 Helps Restrict c-Met-Induced Growth and Therapeutic Resistance of Renal Cancer Cells
2026-10-16 Pages OF1-OF14
Authors: Laxminarayan Rawat, Chiranth M. Prakash, Yuzuru Sasamoto et al.
DOI: 10.1158/1535-7163.mct-26-0483

Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma
2026-10-15
Authors: Katarzyna Radke, Karin Hansson, Subhayan Chattopadhyay et al.
DOI: 10.1158/1535-7163.mct-26-0270

Targeting Pancreatic Cancer with Adenoviral Vectors Equipped with Transgenes
2026-10-14 Pages OF1-OF13
Authors: Brett L. Roach, Mizuho Sato-Dahlman, Kari Jacobsen et al.
DOI: 10.1158/1535-7163.mct-25-1231

Targeting YAP/TEAD signaling disturbs RNA Pol II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer
2026-10-8
Authors: Yan-ting Yann. Zhang, Ayna Mammedova, Dipti Athavale et al.
DOI: 10.1158/1535-7163.mct-25-1491

PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors
2026-10-8
Authors: Sreeja Sreekumar, Migdalia E. Gonzalez, Davis Klein et al.
DOI: 10.1158/1535-7163.mct-26-0239

Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids
2026-10-7
Authors: Thomas S. Dexheimer, Zahra Davoudi, Nathan P. Coussens et al.
DOI: 10.1158/1535-7163.mct-26-0200

GNTbm-38, a Novel Epigenetic Modulator, Performs Immune Activation and Reprogramming of the Tumor Microenvironment
2026-10-7
Authors: Chia-Nan Chen, Cheng-Han Chou, Yi-Hong Wu et al.
DOI: 10.1158/1535-7163.mct-25-1441

Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia
2026-10-6 Pages OF1-OF15
Authors: Haihong Gao, Yi Zhan, Miao Bao et al.
DOI: 10.1158/1535-7163.mct-26-0020